|
A stimulating advance in erythropoiesis for patients with myelodysplastic syndromes |
Sep 2024 |
Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
|
A stimulating advance in erythropoiesis for patients with myelodysplastic syndromes |
Jul 2024 |
Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
|
A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes |
Mar 2019 |
Clin Lymphoma Myeloma Leuk |
Myelodysplastic Syndromes (MDS) |
|
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients |
Nov 2020 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS) |
Mar 2019 |
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
|
A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes |
Nov 2020 |
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation |
Myelodysplastic Syndromes (MDS) |
|
A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes |
Aug 2020 |
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation |
Myelodysplastic Syndromes (MDS) |
|
A Journey from Blood Cells to Genes and Back |
Aug 2023 |
Annual Review of Genomics and Human Genetics |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
A growing panoply of options for patients with paroxysmal nocturnal hemoglobinuria |
Sep 2024 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
A growing panoply of options for patients with paroxysmal nocturnal hemoglobinuria |
Sep 2024 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
